🔗 Share this article

As the United States continues making sweeping revisions to its vaccination recommendations, a particular individual has emerged in a surprising turn: Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by questioning Covid vaccines in the pandemic and has concentrated on potential fatalities after COVID-19 vaccination in her short position at the FDA.

Scheduled Changes to Childhood Immunization Program

Health officials planned to reveal sweeping changes to the pediatric immunization program in December, bringing the US with the Danish national calendar, according to reports – a substantial departure that would place the US at odds with many the global community with little proof for benefit. The announcement has been delayed until the new year.

In place of the director of the vaccine center, Dr. Høeg is set to speak at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to run the office this year.

A Shift at the Regulatory Body

This interim role might represent a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a increased emphasis upon rolling back long-standing immunizations at the FDA.

The new acting director has often pushed for discontinuing specific childhood shot schedules in the US in order to be more in line with Denmark's approach, a nation with universal health coverage and a citizenry about the size of the state of Wisconsin.

So far comments, she has continued to focus on vaccines – usually the domain of Dr. Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Questions Over Background

Høeg has little discernible background in medication creation, regulation or management, which has been typical for previous heads of the CBER. She has been employed at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have the requisite experience” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in running a sizeable institution. She has no expertise in drug approvals.”

Previous heads of CBER would “understand legal statutes and the underlying principles of drug development”, commented Janet Woodcock. “Clearly, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

CDER has an vast workload at the FDA, she emphasized.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office approves numerous off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and other areas, and every single one have to be looked after,” Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a significant leadership component to the role, which manages over 5,000 employees. “It’s a huge administrative position, if you perform it correctly,” Woodcock concluded.

Response and Disputed Policies

Regarding concerns about Høeg’s qualifications and whether this selection signifies increased cooperation among agency officials on immunizations, a press secretary stated that the “concerns rely on incorrect assumptions”.

“Her experience matches the duties of her role,” the representative explained, pointing to the months Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial expedited review system, a controversial rapid therapy clearance system that reportedly troubled her preceding directors. “How are these medications being chosen for this voucher program? Who makes the calls?” Howard said. “There is a lot of lack of transparency going on at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards less stringent regulations of pharmaceuticals, with the exception of immunizations.”

Public Track Record on Vaccines

Regarding immunizations, Høeg has a clearer, if troubling, history, critics have noted. She authored a research paper using unverified volunteer-provided data to determine the frequency of myocarditis after COVID-19 vaccination. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are riskier than they are.

Among her “wish list” for the current government included changing rules for novel immunizations and ending “unnecessary” vaccines, she said following the vote on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of barring teenage boys from receiving Covid vaccines.

“She is an all-around dogmatist who commences with her preconceived notions and reverse-engineers to retrofit the evidence in a highly disingenuous, dishonest manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other dissenters, {like|